Conference Coverage

Disease burden higher in osteoarthritis than rheumatoid arthritis


 

REPORTING FROM OARSI 2018


Functional disability and socioeconomic status are more important predictors of work disability and mortality than “any biomarker or imaging data, except x-ray.” Perhaps, Dr. Pincus said, these could also be important indicators of poor prognosis in OA and all chronic diseases?

“Physical function is a big deal,” he said. Data from a study looking at adults over the age of 50 years in the general Finnish population showed 5-year survival was significantly reduced by poorer functional capacity and less frequent physical exercise, at levels higher than smoking. Perhaps, the musculoskeletal system is more important than the other organs of the body for maintaining health, Dr. Pincus suggested.

Assessing functional status with tools such as the MDHAQ/RAPID3 is “really useful” in daily practice, Dr. Pincus said. He concluded with the words of Rudolph Virchow, who observed more than 100 years ago, that “the improvement of medicine would eventually prolong human life, but improvement of social conditions could achieve this result now and more rapidly and successfully.”

Dr. Pincus is the president of Medical History Services, which receives royalties and license fees from copyright and trademark of MDHAQ, RAPID3, or both, all of which are used to support further development of quantitative clinical measurement by both patients and physicians. He holds stock in the company and has received research funding from the company. Dr. Pincus also disclosed having a consulting agreement with Lilly.

SOURCE: Pincus T et al. Osteoarthritis Cartilage. 2018:26(1):S4. Abstract I-11.

*This story was updated 5/24/2018.

Pages

Recommended Reading

Dermatology practice gaps: improving medication management
MDedge Rheumatology
Upadacitinib for RA shows encouraging results in phase 3 trial
MDedge Rheumatology
MACE risk similar across arthritis subtypes
MDedge Rheumatology
FDA advisory committee recommends baricitinib 2 mg to treat rheumatoid arthritis
MDedge Rheumatology
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Rheumatology
Aim for remission, not low disease activity, in rheumatoid arthritis
MDedge Rheumatology
Obesity and weight loss both linked to RA disability
MDedge Rheumatology
Methotrexate-induced pulmonary fibrosis risk examined in 10-year study
MDedge Rheumatology
VIDEO: Big Data, self-diagnosis to play role in future of RA, expert says
MDedge Rheumatology
VIDEO: Lyme disease spreading, but better testing may be coming
MDedge Rheumatology